A four-month gatifloxacin-containing regimen for treating tuberculosis. - Wikidata - awgldk - TriplyDB

A four-month gatifloxacin-containing regimen for treating tuberculosis.

A four-month gatifloxacin-containing regimen for treating tuberculosis.

http://www.wikidata.org/entity/Q39246235

about

New Antituberculosis Drugs: From Clinical Trial to Programmatic Use Tuberculosis Biomarkers: From Diagnosis to Protection Integrated therapy for HIV and tuberculosis Translational Research for Tuberculosis Elimination: Priorities, Challenges, and Actions Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?Effects of Fluroquinolones in Newly Diagnosed, Sputum-Positive Tuberculosis Therapy: A Systematic Review and Network Meta-Analysis Treatment of Drug Susceptible Pulmonary Tuberculosis World TB Day 2016: an interview with leading experts in tuberculosis research Current strategies to treat tuberculosis Recent Developments and Future Opportunities in the Treatment of Tuberculosis in Children Assessment of treatment response in tuberculosis Driving the Way to Tuberculosis Elimination: The Essential Role of Fundamental Research Persisting positron emission tomography lesion activity and Mycobacterium tuberculosis mRNA after tuberculosis cure Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania The Effectiveness and Safety of Fluoroquinolone-Containing Regimen as a First-Line Treatment for Drug-Sensitive Pulmonary Tuberculosis: A Systematic Review and Meta-Analysis New anti-tuberculosis drugs and regimens: 2015 update The best of respiratory infections from the 2015 European Respiratory Society International Congress The impact of being homeless on the unsuccessful outcome of treatment of pulmonary TB in São Paulo State, Brazil A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)In silico evaluation and exploration of antibiotic tuberculosis treatment regimens Tuberculosis therapy for 2016 and beyond.Challenges in the clinical assessment of novel tuberculosis drugs.Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies.Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.Update in Mycobacterium tuberculosis lung disease 2014.Drug-resistant tuberculosis and advances in the treatment of childhood tuberculosis.Efficacy of ultra-short course chemotherapy for new smear positive drug susceptible pulmonary tuberculosis: study protocol of a multicenter randomized controlled clinical trial.Effects on the QT Interval of a Gatifloxacin-Containing Regimen versus Standard Treatment of Pulmonary Tuberculosis Advancing host-directed therapy for tuberculosis.Month 2 culture status and treatment duration as predictors of recurrence in pulmonary tuberculosis: model validation and update The role of delamanid in the treatment of drug-resistant tuberculosis.Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis Comparative Proteomics of Activated THP-1 Cells Infected with Mycobacterium tuberculosis Identifies Putative Clearance Biomarkers for Tuberculosis Treatment.Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis A sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosets Respiratory Infections in the U.S. Military: Recent Experience and Control The need to accelerate access to new drugs for multidrug-resistant tuberculosis.First insights into circulating Mycobacterium tuberculosis complex lineages and drug resistance in Guinea.Impact of food on the pharmacokinetics of first-line anti-TB drugs in treatment-naive TB patients: a randomized cross-over trial.

P2860

Q26741138-7FC7A604-BC5F-46A5-818A-634241EB657A Q26741141-F45F23AA-5A7C-4418-9035-136184D6BB79 Q26749428-101BF08A-2B7B-47BB-9AE3-6F7278D0A13A Q26765051-A2E2D24C-4F27-4167-88FE-6AF574D2E5A8 Q26771997-663C147C-6E31-427E-83EB-B614E97F087A Q26775757-1B78B9D8-DBB5-4722-B61B-7AC2BB187CE6 Q26801605-D4A2E801-BC28-4915-A08D-2E3D73ACDE42 Q27304811-3600AA5D-AA43-4034-B29F-E57EAE2B9124 Q28075252-2865B911-661B-45F1-B70B-6063995C1E83 Q28085210-3CB566C5-941C-4927-B12C-BCBC1A844B9E Q28384421-5DD34496-BDA9-4E37-AB5E-97EECED7D0BB Q28388018-A7B814D3-0DBC-47A3-A68E-1F0B9F0802B3 Q28391110-D3652AD6-1346-4797-8729-49E37B22A125 Q28550488-888C627F-6DAF-4D49-ACCD-A5AFDD918BB9 Q28553119-17F725A9-3E12-4A1A-98FF-6E0D8F4B3CDC Q28596775-10E61C11-7EAE-45CD-AC6D-B47EC3B4D854 Q28598393-E1E2AD3B-DB55-42F0-916C-B5EA6CF8193E Q28602110-941079BE-2012-44F8-AADA-43A942C7E794 Q28602112-6F269598-B703-4CA9-8D44-836A564AED64 Q28607283-33202F0D-89BF-43E7-A9B8-04106817B3C5 Q30248788-10FEE977-755E-4273-87AF-1141A6C0B375 Q30251933-B0E24A83-0B31-4591-ADF7-8C30C1EF2BFC Q30379233-E4B752E6-CA39-4269-AD2B-905E1177B189 Q30901894-127CCC91-9254-4B2E-A2D8-3EBE8B13C004 Q33735589-CDF42CDA-03E9-4CE2-BAE0-A0E8AAF8618D Q33735642-DA400FA5-CD4E-45E3-A324-CA9C8C554FCB Q33801345-5AD04053-AB25-4066-9F25-D2168FF9B78D Q33810454-ACCC91A8-F111-4A33-8876-5652B9AD0683 Q33843675-16052476-0107-4DB3-B0F1-5BC5EA1FD6D0 Q34466861-2F9A3C45-8A3A-46A8-A80B-1A1AE21A023D Q35617686-1DD70B46-4B5C-4628-9EB8-A5877059E160 Q35624245-95749D98-6A64-40B2-8C6D-8DA230B11322 Q35687128-4DD5B18D-B722-4F6E-A776-49A0637B9C48 Q35716029-1BEA8A29-BF90-426D-A775-104A7454A54E Q35718241-3749D96B-718F-465E-9A2B-6C9B05791983 Q35745991-AAB0A1FF-67C6-4FF5-AC7B-4C5C54860FE5 Q35763405-9FAF2AB9-FE3A-4EDB-AE87-9E651B903D96 Q35815071-3976453D-4AA6-4BD1-8786-576159C51FBE Q35856542-5AF15C41-0BB7-4E00-BAA2-1367E3F4EF18 Q35867681-80A666E0-49AE-4CAA-8A04-86647EF7916F

P2860

A four-month gatifloxacin-containing regimen for treating tuberculosis.

http://www.wikidata.org/entity/Q39246235

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

A four-month gatifloxacin-containing regimen for treating tuberculosis.

@en

A four-month gatifloxacin-containing regimen for treating tuberculosis.

@nl

type

label

A four-month gatifloxacin-containing regimen for treating tuberculosis.

@en

A four-month gatifloxacin-containing regimen for treating tuberculosis.

@nl

prefLabel

A four-month gatifloxacin-containing regimen for treating tuberculosis.

@en

A four-month gatifloxacin-containing regimen for treating tuberculosis.

@nl

P1433

Q39246235-614779EA-CD22-406F-9AE3-271352F1FE05

P1476

Q39246235-69188149-AF01-4FA5-A13B-1C1CECC1E043

P2093

Q39246235-04EE641F-716C-41B8-8FB3-0BEC6A28111C

Q39246235-1230038A-3227-4AF9-BE27-5481F6516B33

Q39246235-16D55A29-8F88-40B9-8ED3-06730BDB1925

Q39246235-22353B2E-85AC-4801-A5AF-61DC9583455B

Q39246235-227A8543-5113-47E9-8662-C37D2478E8EA

Q39246235-2405841E-869F-40F8-8EC7-B3A38AC1A60F

Q39246235-29F6BBFD-A005-4C32-B3B5-3F273AA50D47

Q39246235-3168E1AF-5CF9-4C04-9032-DA637F71B185

Q39246235-33C6394E-5D66-422B-9BCC-0F72D52EF935

Q39246235-58BF698E-5948-4100-AC1C-8A0D00FD58C5

P304

Q39246235-2B89AC4C-F53E-4997-AEB8-19B4C329848F

P31

Q39246235-4672D746-9404-4638-BD21-05C78B894048

P356

Q39246235-17EEEAC6-9E79-43E8-AB69-EB89C77504B4

P407

Q39246235-4D39B64B-D778-4869-A09B-83D461A252ED

P433

Q39246235-7CB9100F-A344-4653-957F-622189ACAFAB

P478

Q39246235-C9BF95F3-48C9-4C79-B67C-0CD20B1A6B7B

P50

Q39246235-30CEEFD1-93CD-4096-8EB9-219921CA2C25

Q39246235-3A0F20BE-7EA8-42D9-8F62-F89CA11C7E48

P577

Q39246235-6B19C4B7-4C9A-4EC9-A02D-4C064076C197

P698

Q39246235-2DBF425A-D31A-412A-B031-32BD2C43DA37

P921

Q39246235-EFFC785A-E8D7-4192-863C-09D3DCFAE991

P356

P1433

The New England Journal of Medicine

P1476

A four-month gatifloxacin-containing regimen for treating tuberculosis.

@en

P2093

Alimatou N'Diaye

http://www.w3.org/2001/XMLSchema#string

Boubacar Bah

http://www.w3.org/2001/XMLSchema#string

Charalambos Sismanidis

http://www.w3.org/2001/XMLSchema#string

Christian Lienhardt

http://www.w3.org/2001/XMLSchema#string

Christian Perronne

http://www.w3.org/2001/XMLSchema#string

Corinne S Merle

http://www.w3.org/2001/XMLSchema#string

Evans Amukoye

http://www.w3.org/2001/XMLSchema#string

Ferdinand Kassa

http://www.w3.org/2001/XMLSchema#string

John Horton

http://www.w3.org/2001/XMLSchema#string

Joseph Odhiambo

http://www.w3.org/2001/XMLSchema#string

P304

1588-1598

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1315817

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

371

http://www.w3.org/2001/XMLSchema#string

P50

Bouke C de Jong

Katherine L Fielding

P577

2014-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25337748

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde